<DOC>
	<DOCNO>NCT00002058</DOCNO>
	<brief_summary>This study examine effectiveness clofazimine prophylaxis Mycobacterium avium complex infection HIV infect individual risk develop untreatable opportunistic disease . In absence truly effective antiretroviral therapy , potential mode treatment patient HIV infection prevent development life-threatening opportunistic infection . Current study demonstrate possible efficacy clofazimine prophylaxis Pneumocystis carinii pneumonia ( PCP ) , common AIDS-defining opportunistic infection . Future study examine potential prophylaxis opportunistic infection . This proposal hop define role prophylactic clofazimine prevent currently untreatable Mycobacterium avium complex infection . AMENDED : To include prophylaxis Asymptomatic ARC .</brief_summary>
	<brief_title>A Randomized Controlled Prophylactic Study Clofazimine To Prevent Mycobacterium Avium Complex Infection HIV Disease</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Clofazimine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Pneumocystis prophylaxis . Antiretroviral therapy , experimental protocol . Antipyretics analgesic per treat physician . Exclusion Criteria Coexisting Condition : Patients follow exclude : Unexplained fever . Night sweat . Unexplained anemia hemoglobin &lt; 10 g percent hematocrit le 30 percent . Hepatic transaminase elevation total bilirubin value &gt; 3 time normal . Longterm ( 2 week ) treatment drug know significant antiMycobacterium avium complex ( MAC ) activity include isoniazid , ethambutol , rifampin , raffia , PAS , PZA , amikacin , streptomycin , ethionamide , viomycin , cycloserine , capreomycin , ciprofloxacin , imipenem , rifapentine , gentamicin , penicillin . Patients follow excluded : Known hypersensitivity clofazimine . Mycobacterium avium complex ( MAC ) infection diagnosis site ( except isolation stool asymptomatic patient ) . Any follow symptom time study entry : Unexplained fever . Night sweat . Unexplained anemia hemoglobin &lt; 10 percent hematocrit le 30 percent . Hepatic transaminase elevation total bilirubin value &gt; 3 time normal . Longterm ( 2 week ) treatment drug know significant antiMAC activity . Prior Medication : Excluded : Longterm ( 2 week ) treatment drug know significant antiMycobacterium avium complex ( MAC ) activity include isoniazid , ethambutol , rifampin , raffia , PAS , PZA , amikacin , streptomycin , ethionamide , viomycin , cycloserine , capreomycin , ciprofloxacin , imipenem , rifapentine , gentamicin , penicillin . Group 1 : AIDS patient first episode Pneumocystis carinii pneumonia ( PCP ) within 2 4 month prior study entry . Group 2 : Patients T4 count &lt; 100 cells/mm3 , regardless prior opportunistic infection malignancy . Karnofsky = &gt; 70 . All patient must sign informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1990</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Mycobacterium avium-intracellulare Infection</keyword>
	<keyword>Clofazimine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>